Indivior Pharmaceuticals Inc (INDV) financials
Indivior Pharmaceuticals revenue and earnings by year
Indivior Pharmaceuticals's revenue was $1.24 billion in the fiscal year to December 31, 2025, up 4.3% from the year before. Net income was $210 million, 16.9% of revenue. Since the fiscal year to December 31, 2020, revenue has grown 13.9% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 6 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
| Revenue | 1.24 | 1.19 | 1.09 | 0.90 | 0.79 | 0.65 |
| Revenue growth | 4.3% | 8.7% | 21.3% | 13.9% | 22.3% | — |
| Gross profit | 0.99 | 0.96 | 0.92 | 0.75 | 0.66 | 0.55 |
| Gross margin | 80.1% | 80.6% | 84.1% | 83.2% | 83.9% | 85.0% |
| Operating income | 0.26 | 0.04 | -0.15 | -0.08 | 0.21 | -0.16 |
| Operating margin | 21.1% | 3.2% | -14.1% | -9.0% | 26.9% | -24.1% |
| Net income | 0.21 | 0.01 | -0.13 | -0.04 | 0.21 | -0.15 |
| Net margin | 16.9% | 0.6% | -11.5% | -4.9% | 25.9% | -22.9% |
| Diluted EPS | $1.64 | $0.05 | -$0.94 | -$0.32 | — | — |
| Free cash flow | -0.09 | 0.01 | -0.31 | -0.01 | 0.38 | -0.15 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open INDV in Markets.
See also: INDV valuation and P/E history · INDV returns
No forecast, no recommendation. This page describes Indivior Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.